Amy Kruse is the chief investment officer of Satori Neuro, a fund focused on mental health, neurotechnology, and human flourishing. She brings decades of experience spanning neuroscience, technology R&D, government, business leadership, and venture investment, with a particular focus on translating emerging science and complex technologies into real-world applications.

Prior to Satori Neuro, Amy was a general partner at Prime Movers Lab, where she led life sciences investments in human augmentation and longevity. She previously served as chief scientific officer of Optios and vice president and chief technology officer of Cubic Global Defense, where she oversaw R&D programs. Earlier in her career, Amy was a program manager at DARPA, where she created and led the agency’s first performance-oriented neuroscience programs.

Amy serves on several company boards and advises organizations across the neuroscience, defense, and innovation communities. She earned a Ph.D. in neuroscience and a B.S. in cell and structural biology from the University of Illinois Urbana-Champaign, where she was awarded a National Science Foundation Graduate Fellowship.